Search
Piboserod
go.drugbank.com/drugs/DB04873InvestigationalPiboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
Methacholine
go.drugbank.com/drugs/DB06709ApprovedAsthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Beclamide
go.drugbank.com/drugs/DB09011ExperimentalBeclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity. It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicit[A177754] Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the … Moderna Bivalent vaccine elicit a higher seroresponse both against the original SARS-CoV-2 strain and the BA.4/5 strain compared to that of the Moderna COVID-19 Vaccine.